Kyverna Therapeutics, Inc. (KYTX) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $24.88M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $24.74M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2025-10-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD $150.00M; Debt Instrument, Face AmountUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2022-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD $1.10M; Debt Instrument, Interest Rate, Stated Percentagepure 4.27%.
Kyverna Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure |
|---|---|---|---|---|
| 2026-06-30 | $24.88M | (m) | (m) | (m) |
| 2025-12-31 | $24.74M | (m) | (m) | (m) |
| 2025-10-31 | (m) | $150.00M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $1.10M | 4.27% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |